Krystal Biotech (KRYS) Cash from Investing Activities (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Cash from Investing Activities data on file, last reported at -$63.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 16.09% year-over-year to -$63.6 million; the trailing twelve-month figure through Mar 2026 stood at -$67.2 million (up 65.03% YoY), and the FY2025 full-year result was -$58.4 million, up 64.26% from the prior year.
• Cash from Investing Activities fell to -$63.6 million in Q1 2026, from $11.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $105.2 million in Q3 2023 to a low of -$83.8 million in Q4 2024.
• A 5-year average of -$18.6 million and a median of -$16.0 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities slumped 7384.34% in 2022 and surged 813.5% in 2023, its largest moves.
• Tracing KRYS's Cash from Investing Activities over 5 years: stood at -$5.2 million in 2022, then sank by 95.08% to -$10.2 million in 2023, then slumped by 724.59% to -$83.8 million in 2024, then soared by 113.32% to $11.2 million in 2025, then tumbled by 669.59% to -$63.6 million in 2026.
• Business Quant data shows KRYS's Cash from Investing Activities at -$63.6 million in Q1 2026, $11.2 million in Q4 2025, and -$4.3 million in Q3 2025.